| 
			 
			For more information please contact:   Investment Banking 
			
			Eric B. Cheng 
			Managing Director Co-Head of Healthcare Investment Banking 
			(646) 358-1901 
			
			echeng@roth.com
			   
			
			James Antonopoulos 
			Managing Director Co-Head of Healthcare Investment Banking 
			(646) 358-1906 
			
			
			jantonopoulos@roth.com   
			
			
			Aparna Beeram 
			Vice President 
			(646) 358-1912 
			
			abeeram@roth.com   
			Equity Capital Markets 
			
			Aaron Gurewitz 
			Head of Equity 
			Capital Markets 
			(949) 720-5703 
			
			agurewitz@roth.com 
			  
			
			Nazan Akdeniz 
			Senior Vice President 
			(949) 720-5740 
			
			nakdeniz@roth.com 
			  
			
			Lou Ellis 
			Senior Vice President 
			(949) 720-5739 
			
			lellis@roth.com  | 
			
			 
			Transaction Information 
						Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, has closed an underwritten public offering of 2,143,000 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 2,143,000 shares of common stock.   
  
Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one investor warrant to purchase one share of common stock at a combined offering price of $7.00, resulting in the gross proceeds for Myomo of approximately $15.0 million.   
  
The investor warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire five years from the date of issuance.   Myomo has granted the underwriters a 45-day option to purchase an additional 321,450 shares of common stock, and/or investor warrants to purchase up to 321,450 shares of common stock, in any combinations thereof, at the public offering price per security, less the underwriting discounts and commission. 
  
ROTH Capital Partners acted as sole book-running manager for the offering.
  
About Myomo 
						Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line.  For more information, please visit 
			https://myomo.com. 
			(Source: Company Press Release | 02/11/20)
			
  About ROTH Capital Partners 
			ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and 
			their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, 
			market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and 
			maintains offices throughout the U.S. For more information on ROTH, please visit 
			www.roth.com.  | 
		
		
			| 
			 
			Date of Announcement: 02/14/20 
			The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC 
			("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any 
			companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an 	offer or solicitation of the securities discussed. Any opinions or 
			estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ 
			materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be 
			reproduced in any form without the express written permission of ROTH. Copyright 2020.  |